Brain scan technology helps address mental health issues SoCal firefighters, first responders face
A 2023 study by the National Highway Traffic Safety Administration showed that first responders and law enforcement workers were more likely to die by suicide than in the line of duty.
Dr. Daniel Amen, a psychiatrist and author, uses a SPECT scan on his patients at his mental healthcare clinics. A SPECT scan involves 3-D scans of the patient's brain that look at blood flow and activity, followed by a custom treatment plan.
Matt Fiorenza is a retired firefighter-paramedic who spent 22 years with the Anaheim Fire Department. In his career, he's witnessed people's worst tragedies while constantly working on the frontlines of death and destruction.
'I remember doing a stress debriefing after a woman's boyfriend had run over their 2-year-old child,' Fiorenza said. 'I remember looking down at this child and seeing the diapers.'
That painful memory is just one of many incidents that Fiorenza said had sent him on a downward spiral during his career. As he continued witnessing one traumatic event after the next, he tried to cope but began struggling with alcohol and drug abuse.
'I got diagnosed in 2015 with what we know now is PTSD (Post-Traumatic Stress Disorder),' Fiorenza said. 'And back then, in the first responder community, they really didn't know what to do with me.'
After struggling and hitting rock bottom, Fiorenza said he attempted suicide three different times.
'I racked [a gun] and put it in my mouth and my wife heard it and came in and wrestled the gun away,' Fiorenze recalled.
He eventually went back to seek professional treatment, but said the process was never enough for him. After isolating in his apartment for four months, he knew he needed more help. That's when he met Dr. Daniel Amen and received a SPECT scan on his brain.
Amen is a psychiatrist and author who operates mental health clinics throughout Southern California and the U.S. Amen uses a SPECT scan to take 3-D images of the brain to examine blood flow and activity.
'When we look at his active brain, his emotional brain, that's the red and white [colors], it's working way too hard, which is why it just feels awful inside,' Amen explained of the SPECT images of Fiorenze's brain.
Amen said the images can be a powerful tool to diagnose underlying problems in the brain. In Fiorenze's case, Amen said the scans showed signs of PTSD and traumatic brain injury.
'Looking at a picture of my brain, it just took the stigma out of it,' Fiorenze said. 'It's like, okay, I'm not crazy.'
After a patient receives a SPECT scan, a custom treatment plan is devised.
For Fiorenze, that plan included EMDR (Eye movement desensitization and reprocessing) therapy, supplements, and hyperbaric oxygen therapy — tools he said dramatically changed his life.
After two years of the custom treatment plan, Amen took a new SPECT image of Fiorenze's brain to see the progress.
'His cerebellum is healthier and his emotional brain calmed down,' Amen explained of the new images.
'I think that for firefighters, seeing is believing,' said Dr. Gina Gallivan, a police and public safety psychologist.
Gallivan said that while she doesn't include SPECT scans as part of her treatment protocols, she believes the results can motivate firefighters to seek help.
'The first responders I have spoken to who have had brain scans and they see the visible damage to their brain and it was very impactful for them,' she said.
'What you see among untreated firefighters is a higher incidence of divorce, a higher incidence of bankruptcy, a higher incidence of depression and a significantly higher incidence of suicidal behavior,' Amen said.
Amen has been using SPECT scans for 34 years, however, he acknowledges there are some critics of the practice.
'It's incredibly frustrating that psychiatrists remain the only medical doctors who virtually never look at the organ they treat,' he said.
Currently, insurance does not cover a SPECT scan, but Amen Clinics has a 'Change Your Brain Foundation' to raise money for education, research and services.
The foundation covered the full cost of Fiorenze's scan and treatment. Recent donations also mean the company currently has enough funding to provide 100 SPECT scans for firefighters and first responders who were impacted by the recent fires in Southern California.
Fiorenze said he hopes that by sharing his story, he can remove the stigma of receiving mental healthcare while also helping his peers who may be struggling.
Information about Amen Clinics and the SPECT scan can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
California doctor sued for ‘wrongful death' after shipping abortion drugs interstate in legal first
A Texas man is suing a doctor in California he claims mailed his girlfriend pills to end her pregnancy - in what may be a legal first - and a test of new state abortion laws. Jerry Rodriguez filed a wrongful death lawsuit against Remy Coeytaux, after the doctor sent the abortion-inducing drugs across state lines in order to 'murder his unborn son,' Rodriguez claimed. It appears to be the first time an interstate lawsuit for wrongful death over an abortion has been filed, according to The Washington Post. In Texas, a person who assists a pregnant woman in obtaining a self-managed abortion commits the crime of murder and can be sued for wrongful death, the lawsuit, filed in Texas federal court and obtained by The Independent, states. The woman herself cannot be prosecuted. The suit adds it is also a state jail felony for anyone other than a Texas-licensed physician to provide an abortion-inducing drug for the purpose of inducing an abortion. 'In violation of these and many other laws, defendant Remy Coeytaux mailed abortion-inducing drugs into Texas that were used to murder Jerry Rodriguez's unborn child,' the complaint reads. Rodriguez is suing Coeytaux for $75,000 over what he claims is wrongful death. He's also seeking an injunction to stop the doctor from distributing abortion-inducing drugs in violation of state or federal law. The injunction, the suit states, is being sought 'on behalf of a class of all current and future fathers of unborn children in the United States.' But such state legislation clashes with that of California, which retains a so-called 'Shield Law' to protect medical professionals such as Coeytaux. The law provides that 'California will not deliver a person accused or charged with committing a crime related to abortion/gender-affirming care over to law enforcement officials.' This includes situations where a California-licensed pharmacist dispenses an abortion-inducing drug mifepristone to a patient in a state with abortion-restrictive laws. According to Rodriguez's suit, he began dating his girlfriend in June 2024, while she was separated from her husband, but not yet divorced. The Independent has chosen not to name the woman, due to privacy reasons and because she is not a defendant in the lawsuit. The suit alleges that the woman's husband, Adam Garza, twice ordered the abortion medication from Coeytaux after she became pregnant by Rodriguez 'with the intent of using them to murder Mr. Rodriguez's unborn child,' and 'pressured her' to take the pills. A Venmo receipt confirming Garza's purchase of the drugs from Coeytaux was included in the lawsuit, with a reference of ''Aed axes' – allegedly a homonym for 'Aid Access,' an organization that ships abortion-inducing drugs into jurisdictions where abortion is not legal. 'Defendant Coeytaux caused the death of Mr. Rodriguez's unborn child through his wrongful acts,' the lawsuit states. 'Although [the woman] cannot be charged with murder for her role in killing her unborn child, her immunity does not shield Coeytaux from liability for aiding or abetting or directly participating in the murder.' 'Mr. Rodriguez seeks this injunction on behalf of a class of all current and future fathers of unborn children in the United States.' The Independent has reached out to Dr Remy Coeytaux for comment on the lawsuit.


Newsweek
2 days ago
- Newsweek
US Birth Rate Plunges to New Low — CDC
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The United States' total fertility rate fell to a record low in 2024, dipping below 1.6 children per woman, according to new federal data released Thursday by the Centers for Disease Control and Prevention (CDC). This marks a significant demographic milestone for a country that once stood apart among developed nations for maintaining a replacement-level birth rate of around 2.1 children per woman. The U.S. fertility rate, once buoyed by post-World War II baby booms and comparatively high birth rates among younger women, has been steadily declining for nearly two decades. Many women are delaying motherhood or opting out of having children altogether — a trend now bringing American fertility rates closer to those of Western Europe. World Bank data confirms this alignment with long-standing European demographic patterns. The toes of a baby are seen at a hospital in McAllen, Texas, on Wednesday, July 29, 2020. The toes of a baby are seen at a hospital in McAllen, Texas, on Wednesday, July 29, 2020. Associated Press Despite concern in some political circles, experts suggest the falling birth rate reflects broader cultural and economic shifts, rather than an imminent population crisis. "We're seeing this as part of an ongoing process of fertility delay," said Leslie Root, a fertility and population policy researcher at the University of Colorado Boulder. "We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths." Nevertheless, declining fertility has captured the attention of policymakers. In response to the trend, the Trump administration has advocated for several pro-natal measures, including an executive order aimed at expanding access to and reducing the cost of in vitro fertilization. The administration has also floated the idea of "baby bonuses" to incentivize family growth. But critics argue that these proposals are unlikely to reverse the trend without addressing deeper structural issues. Karen Guzzo, director of the Carolina Population Center at the University of North Carolina, said many young people are simply not ready to start families due to financial uncertainty, lack of support systems, and late marriages. "Worry is not a good moment to have kids," she explained. "And that's why birth rates in most age groups are not improving." Asked about the administration's initiatives, Guzzo was skeptical: "The things that they are doing are really symbolic and not likely to budge things for real Americans." She emphasized that lasting change would require more comprehensive policies, such as paid parental leave and affordable child care. The CDC's updated figures for 2024 show that the total fertility rate dropped from 1.621 in 2023 to 1.599. That statistic is derived from a more detailed analysis of birth certificates and replaced earlier provisional estimates. Interestingly, the new report also shows a 1% increase in overall births — roughly 33,000 more babies — compared to 2023, bringing the total to just over 3.6 million. However, this does not reflect a higher birth rate. The CDC clarified that the discrepancy stemmed from recalculated population estimates, which now account for an increase in women of childbearing age due to immigration. "That's plausible," Root said. "As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups." Ultimately, both experts agree the U.S. faces a complex demographic shift shaped by economics, policy, and evolving personal choices. This article includes reporting by the Associated Press.
Yahoo
3 days ago
- Yahoo
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Patent-protected methylone-inspired analogs support pipeline expansion into PTSD CAMBRIDGE, Mass., July 23, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent application, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders. "With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care." Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain. Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints. "The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment," added Dr. Tucker. "We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs" About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on Contacts Investor RelationsTiberend Strategic Advisors, Inc. David Irish(231) 632-0002dirish@ Media RelationsTiberend Strategic Advisors, Inc. Casey McDonald(646) 577-8520cmcdonald@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data